Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial ☆
Titel:
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial ☆
Auteur:
Spring, L.M. Tolaney, S.M. Fell, G. Bossuyt, V. Abelman, R.O. Wu, B. Maheswaran, S. Trippa, L. Comander, A. Mulvey, T. McLaughlin, S. Ryan, P. Ryan, L. Abraham, E. Rosenstock, A. Garrido-Castro, A.C. Lynce, F. Moy, B. Isakoff, S.J. Tung, N. Mittendorf, E.A. Ellisen, L.W. Bardia, A.